You can also read the IBTA e-News December 2018 edition in full online here.
Some of the highlights from this month's round-up:
- Following the successes of 2018, the IBTA is delighted to announce that the next International Brain Tumour Awareness Week will be taking place from Saturday, 26 October to Saturday, 2 November 2019 inclusive. Read more about the IBTA’s awareness-raising initiatives on our website here.
- The National Cancer Institute (NCI) – the US government's principal agency for cancer research – has announced funding totalling $4 million for new adult and paediatric brain tumour research projects.
- EORTC, European Organization for Research and Treatment of Cancer, in collaboration with the Canadian Cancer Trials Group and funding from Celgene Corporation are conducting a new trial, the EORTC-1709-BTG, which is a Phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
- The All.Can initiative has presented findings of its UK patient survey at a UK Parliamentary event. They showed that 36% of people considered the cancer diagnosis stage as the biggest cause of inefficiency in their care.
- A randomised, multicentre phase 2 trial performed across ten centres in Italy has demonstrated an “encouraging overall survival benefit” of the anticancer agent regorafenib in recurrent glioblastoma, according to results published in The Lancet Oncology.
- Results of experiments published in the International Journal of Molecular Sciences have shown that the anticancer agent sorafenib appears to make glioblastoma cells more sensitive to tumour-treating fields (TTFields), suggesting a potential combination therapy.A study published in the journal Cancer Epidemiology, Biomarkers and Prevention has examined the association between glioma and aspirin or non-steroidal anti-inflammatory drug (NSAID) use, showing that a history of daily aspirin use for six months or longer was associated with a 38% lower glioma risk.
- Findings from experiments on brain tumour cells published in Scientific Reports support the idea that increasing levels of microRNAs may be a potential means of treating paediatric low-grade gliomas (PLGG).
- The Global Coalition for Adaptive Research (GCAR) and Bayer have announced that Bayer’s regorafenib will be the first drug to enter “GBM AGILE” (Glioblastoma Adaptive Global Innovative Learning Environment), which is a revolutionary patient-centred adaptive platform trial that will evaluate multiple therapies for patients with newly diagnosed and recurrent glioblastoma.
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.
To see an archive of existing e-News issues, click here.